LA-HCM Study : Rivaroxaban for Antithrombotic Prevention in Hypertrophic Cardiomyopathy Patients With Abnormal Left Atrial Strain.

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 532 participants.

Also called NCT07202897

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 532 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07202897
  • EU CT 2024-511084-28-00
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
France (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07202897. Randomized; no masking; primary purpose prevention. Start 2026-01-07 (actual); primary completion 2032-01-07 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
LA-HCM Study : Rivaroxaban for Antithrombotic Prevention in Hypertrophic Cardiomyopathy Patients With Abnormal Left Atrial Strain.
Acronym
LA-HCM
Condition
Hypertrophic Cardiomyopathy (HCM)
Intervention (Drug)
Anticoagulant treatment Rivaroxaban
Intervention (Other)
Best medical therapy
Lead sponsor
Rennes University Hospital (class: other)

Record details

Record id
cardio:ct-nct07202897
Content hash
1a9df0cc02bd3fefd59acdbc8c8d0c3781dbc3ee0fda6baea3548c224b611622